Insight Molecular DiagnosticsIMDX +0.88%49 Cyclically Adjusted PS Ratio is 19.79 as of Jul. 04, 2026, which is 97% above its 10-year median of 10.03. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.25 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 134 Medical Diagnostics & Research companies, Insight Molecular Diagnostics ranks worse than 94.03% on this metric.
The historical rank and industry rank for Insight Molecular Diagnostics's Cyclically Adjusted PS Ratio or its related term are showing as below:
IMDX'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 6.28 Med: 10.03 Max: 25.66
Current: 19.88
During the past years, Insight Molecular Diagnostics's highest Cyclically Adjusted PS Ratio was 25.66. The lowest was 6.28. And the median was 10.03.
IMDX's Cyclically Adjusted PS Ratio is ranked worse than 94.03% of 134
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.015
vs IMDX: 19.88
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Insight Molecular Diagnostics's adjusted revenue per share data for the three months ended in Mar. 2026 was $0.001. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.29 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Insight Molecular Diagnostics (NAS:IMDX) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Insight Molecular Diagnostics Cyclically Adjusted PS Ratio Related Terms
Insight Molecular Diagnostics Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics Cyclically Adjusted PS Ratio Chart
IMDX vs XGN, BDSX, BNR: Cyclically Adjusted PS Ratio Comparison
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's Cyclically Adjusted PS Ratio falls into.
Insight Molecular Diagnostics Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 19.79 mean?
Insight Molecular Diagnostics (IMDX) has a Cyclically Adjusted PS Ratio of 19.79 as of Jul. 04, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Insight Molecular Diagnostics and its competitors. This is 97% above median its historical median of 10.03. Over the past decade, Insight Molecular Diagnostics' Cyclically Adjusted PS Ratio has ranged from 6.28 to 25.66. According to the industry distribution chart, Insight Molecular Diagnostics ranks #126 out of 134 companies in the Medical Diagnostics & Research industry, placing it in the top 94%.
Is Insight Molecular Diagnostics' Cyclically Adjusted PS Ratio too high?
Insight Molecular Diagnostics' current Cyclically Adjusted PS Ratio of 19.79 is 97% above median its 10-year median of 10.03. Over the past 10 years, this metric has ranged from a low of 6.28 to a high of 25.66. The Medical Diagnostics & Research industry median Cyclically Adjusted PS Ratio is 2.02. Insight Molecular Diagnostics' value of 19.79 is 882.1% above this industry median. Based on the distribution chart, Insight Molecular Diagnostics ranks #126 out of 134 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Cyclically Adjusted PS Ratio compare to XGN and BDSX?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #126 out of 134 companies for Cyclically Adjusted PS Ratio. This places Insight Molecular Diagnostics in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.02. Insight Molecular Diagnostics' value of 19.79 is 882.1% above this benchmark. Historically, Insight Molecular Diagnostics' own Cyclically Adjusted PS Ratio has ranged from 6.28 to 25.66 over the past decade. While the company's 10-year median is 10.03 vs. the industry median of 2.02, Insight Molecular Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PS Ratio among Medical Diagnostics & Research companies is 2.02, based on 134 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insight Molecular Diagnostics's current Cyclically Adjusted PS Ratio of 19.79 is 882.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Insight Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PS Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insight Molecular Diagnostics's current Cyclically Adjusted PS Ratio is 19.79, which is 97% above median its own 10-year median of 10.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $5.74 — trading 359.2% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 19.79, which is 97% above median its 10-year median of 10.03 and 882.1% above the Medical Diagnostics & Research industry median of 2.02. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Cyclically Adjusted PS Ratio is 19.79 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $5.74 is trading 359.2% above its estimated GF Value™ of $1.25.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for IMDX:
Cyclically Adjusted PS Ratio: 19.79 (97% above median its 10-year median of 10.03)
GF Value™: $1.25 vs. price of $5.74 (359.2% above fair value)
Industry Position: 882.1% above the Medical Diagnostics & Research median (#126 of 134)
No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Business Description
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score
Get the complete analysis for IMDX
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMDX has been successfully added to your 
